Literature DB >> 22476529

Henipaviruses in their natural animal hosts.

D J Middleton1, H M Weingartl.   

Abstract

Hendra virus (HeV) and Nipah virus (NiV) form a separate genus Henipavirus within the family Paramyxoviridae, and are classified as biosafety level 4 pathogens due to their high case fatality rate following human infection and because of the lack of effective vaccines or therapy. Both viruses emerged from their natural reservoir during the last decade of the twentieth century, causing severe disease in humans, horses and swine, and infecting a number of other mammalian species. The current review summarizes our up to date understanding of pathology and pathogenesis in the natural reservoir species, the Pteropus bat, and in the equine and porcine spill over species.

Entities:  

Mesh:

Year:  2012        PMID: 22476529     DOI: 10.1007/82_2012_210

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  18 in total

1.  Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay.

Authors:  Hatem A Elshabrawy; Jilao Fan; Christine S Haddad; Kiira Ratia; Christopher C Broder; Michael Caffrey; Bellur S Prabhakar
Journal:  J Virol       Date:  2014-02-05       Impact factor: 5.103

2.  Hendra virus and Nipah virus animal vaccines.

Authors:  Christopher C Broder; Dawn L Weir; Peter A Reid
Journal:  Vaccine       Date:  2016-05-04       Impact factor: 3.641

3.  Serological Hendra Virus Diagnostics Using an Indirect ELISA-Based DIVA Approach with Recombinant Hendra G and N Proteins.

Authors:  Anne Balkema-Buschmann; Kerstin Fischer; Leanne McNabb; Sandra Diederich; Nagendrakumar Balasubramanian Singanallur; Ute Ziegler; Günther M Keil; Peter D Kirkland; Maren Penning; Balal Sadeghi; Glenn Marsh; Jennifer Barr; Axel Colling
Journal:  Microorganisms       Date:  2022-05-25

4.  A recombinant Hendra virus G glycoprotein subunit vaccine protects nonhuman primates against Hendra virus challenge.

Authors:  Chad E Mire; Joan B Geisbert; Krystle N Agans; Yan-Ru Feng; Karla A Fenton; Katharine N Bossart; Lianying Yan; Yee-Peng Chan; Christopher C Broder; Thomas W Geisbert
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

Review 5.  Zoonotic Potential of Emerging Paramyxoviruses: Knowns and Unknowns.

Authors:  Patricia A Thibault; Ruth E Watkinson; Andres Moreira-Soto; Jan F Drexler; Benhur Lee
Journal:  Adv Virus Res       Date:  2017-02-02       Impact factor: 9.937

6.  A possible outbreak of swine influenza, 1892.

Authors:  David M Morens; Jeffery K Taubenberger
Journal:  Lancet Infect Dis       Date:  2013-11-28       Impact factor: 25.071

7.  Nipah virus entry and egress from polarized epithelial cells.

Authors:  Boris Lamp; Erik Dietzel; Larissa Kolesnikova; Lucie Sauerhering; Stephanie Erbar; Hana Weingartl; Andrea Maisner
Journal:  J Virol       Date:  2013-01-02       Impact factor: 5.103

8.  Protection against henipaviruses in swine requires both, cell-mediated and humoral immune response.

Authors:  Brad S Pickering; John M Hardham; Greg Smith; Eva T Weingartl; Paul J Dominowski; Dennis L Foss; Duncan Mwangi; Christopher C Broder; James A Roth; Hana M Weingartl
Journal:  Vaccine       Date:  2016-08-17       Impact factor: 3.641

9.  Discovery of a bovine enterovirus in alpaca.

Authors:  Shasta D McClenahan; Gail Scherba; Luke Borst; Richard L Fredrickson; Philip R Krause; Christine Uhlenhaut
Journal:  PLoS One       Date:  2013-08-12       Impact factor: 3.240

10.  Hendra virus vaccine, a one health approach to protecting horse, human, and environmental health.

Authors:  Deborah Middleton; Jackie Pallister; Reuben Klein; Yan-Ru Feng; Jessica Haining; Rachel Arkinstall; Leah Frazer; Jin-An Huang; Nigel Edwards; Mark Wareing; Martin Elhay; Zia Hashmi; John Bingham; Manabu Yamada; Dayna Johnson; John White; Adam Foord; Hans G Heine; Glenn A Marsh; Christopher C Broder; Lin-Fa Wang
Journal:  Emerg Infect Dis       Date:  2014-03       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.